- Conditions
- Atrial Fibrillation
- Interventions
- Exercise
- Procedure
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–42
of 18
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
- Interventions
- Placebo, DISC-1459
- Drug
- Lead sponsor
- Disc Medicine, Inc
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 11
- States / cities
- Huntington Beach, California • San Francisco, California • Miami, Florida + 7 more
- Conditions
- Erythropoietic Protoporphyria
- Interventions
- DISC-1459
- Drug
- Lead sponsor
- Disc Medicine, Inc
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • San Francisco, California • Miami, Florida + 7 more
- Conditions
- Acute Hepatic Porphyria, Acute Intermittent Porphyria, Porphyria, Acute Intermittent, Acute Porphyria, Hereditary Coproporphyria (HCP), Variegate Porphyria (VP), ALA Dehydratase Deficient Porphyria (ADP)
- Interventions
- Givosiran, Placebo
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • San Francisco, California • Boston, Massachusetts + 7 more
- Conditions
- Erythropoietic Protoporphyria
- Interventions
- Afamelanotide, Placebo
- Drug
- Lead sponsor
- Clinuvel Pharmaceuticals Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • San Francisco, California • Detroit, Michigan + 4 more
- Conditions
- Tay-Sachs Disease, Porphyria, Erythropoietic, Leukodystrophy, Globoid Cell, Metabolism, Inborn Errors
- Interventions
- Not listed
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 0 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
- Interventions
- Dersimelagon, Placebo
- Drug
- Lead sponsor
- Tanabe Pharma America, Inc.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 13
- States / cities
- Huntington Beach, California • San Francisco, California • Miami, Florida + 10 more
- Conditions
- Erythropoietic Protoporphyria
- Interventions
- Colestipol
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 22 Years to 60 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Erythropoietic Protoporphyria, EPP, X-Linked Protoporphyria, XLP, XLPP, X-Linked Dominant Erythropoietic Protoporphyria, XLEPP, XLDP
- Interventions
- Not listed
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- Not listed
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • San Francisco, California • New York, New York + 3 more
- Conditions
- Acute Hepatic Porphyria, Hepatic Porphyrias, Acute Intermittent Porphyria (AIP), Hereditary Coproporphyria (HCP), Variegate Porphyria (VP), ALA Dehydratase Deficient Porphyria (ADP), Porphyria Acute
- Interventions
- Not listed
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 12
- States / cities
- Pasadena, California • Jacksonville, Florida • Margate, Florida + 9 more
- Conditions
- Erythropoietic Protoporphyria
- Interventions
- Afamelanotide, Placebo
- Drug
- Lead sponsor
- Clinuvel Pharmaceuticals Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • San Francisco, California • New York, New York + 3 more
- Conditions
- Porphyria Cutanea Tarda
- Interventions
- Not listed
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 0 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Congenital Erythropoietic Porphyria (CEP)
- Interventions
- ATL-001 (Ciclopirox oral solution)
- Drug
- Lead sponsor
- Atlas Molecular Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Porphyria Cutanea Tarda
- Interventions
- Hydroxychloroquine, Phlebotomy
- Drug · Procedure
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2021
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Porphyria
- Interventions
- luteinizing hormone-releasing factor
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 18 Years to 55 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1987
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Porphyria
- Interventions
- heme arginate, tin mesoporphyrin
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 2
- States / cities
- New York, New York • Galveston, Texas
- Conditions
- Acute Intermittent Porphyria
- Interventions
- givosiran (ALN-AS1), Sterile Normal Saline (0.9% NaCl)
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • San Francisco, California • New York, New York + 1 more
- Conditions
- Erythropoietic Protoporphyria (EPP), X Linked Erythropoietic Protoporphyria
- Interventions
- Isoniazid
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah